Catalyst Biosciences Inc.

4.59-0.1500-3.16%Vol 152.04K1Y Perf -10.12%
Apr 19th, 2021 14:20 DELAYED
BID4.57 ASK4.59
Open4.71 Previous Close4.74
Pre-Market4.80 After-Market-
 0.06 1.27%  - -
Target Price
16.33 
Analyst Rating
Strong Buy 1.50
Potential %
255.77 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★+     54.08
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap143.81M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
12.95 
Earnings Date
10th May 2021

Today's Price Range

4.494.78

52W Range

4.058.22

5 Year PE Ratio Range

-1.70-0.9000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.24%
1 Month
-22.55%
3 Months
-27.41%
6 Months
-26.00%
1 Year
-10.12%
3 Years
-82.11%
5 Years
-80.37%
10 Years
-99.75%

TickerPriceChg.Chg.%
CBIO4.59-0.1500-3.16
AAPL134.720.56000.42
GOOG2 301.253.49000.15
MSFT258.95-1.7900-0.69
XOM56.13-0.5300-0.94
WFC44.230.39000.89
JNJ162.480.24000.15
FB302.00-4.1800-1.37
GE13.410.02000.15
JPM153.14-0.1600-0.10
Financial StrengthValueIndustryS&P 500US Markets
4.60
5.00
0.01
0.02
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
56.30
-273.90
-273.20
-201 808.00
-
RevenueValueIndustryS&P 500US Markets
4.58M
0.15
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.89-0.863.37
Q03 2020-0.95-0.7323.16
Q02 2020-1.05-0.968.57
Q01 2020--0.28-
Q04 2019-1.23-1.230.00
Q03 2019-1.19-1.0610.92
Q02 2019-1.20-1.154.17
Q01 2019-0.87-1.26-44.83
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.98-19.51Negative
6/2021 QR-1.00-17.65Negative
12/2021 FY-2.757.72Positive
12/2022 FY-2.93--
Next Report Date10th May 2021
Estimated EPS Next Report-0.98
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume152.04K
Shares Outstanding31.33M
Trades Count1.36K
Dollar Volume2.38M
Avg. Volume462.42K
Avg. Weekly Volume245.92K
Avg. Monthly Volume256.53K
Avg. Quarterly Volume496.97K

Catalyst Biosciences Inc. (NASDAQ: CBIO) stock closed at 4.74 per share at the end of the most recent trading day (a -1.46% change compared to the prior day closing price) with a volume of 239.96K shares and market capitalization of 143.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 34 people. Catalyst Biosciences Inc. CEO is Nassim Usman.

The one-year performance of Catalyst Biosciences Inc. stock is -10.12%, while year-to-date (YTD) performance is -24.88%. CBIO stock has a five-year performance of -80.37%. Its 52-week range is between 4.05 and 8.22, which gives CBIO stock a 52-week price range ratio of 12.95%

Catalyst Biosciences Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 1.33, a price-to-sale (PS) ratio of 33.93, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -55.64%, a ROC of -58.05% and a ROE of -74.75%. The company’s profit margin is -%, its EBITDA margin is -273.20%, and its revenue ttm is $4.58 Million , which makes it $0.15 revenue per share.

Of the last four earnings reports from Catalyst Biosciences Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.98 for the next earnings report. Catalyst Biosciences Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Catalyst Biosciences Inc. is Strong Buy (1.5), with a target price of $16.33, which is +255.77% compared to the current price. The earnings rating for Catalyst Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalyst Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalyst Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.45, ATR14 : 0.41, CCI20 : -161.35, Chaikin Money Flow : -0.32, MACD : -0.37, Money Flow Index : 33.89, ROC : -3.85, RSI : 41.05, STOCH (14,3) : 17.33, STOCH RSI : 0.00, UO : 42.57, Williams %R : -82.67), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalyst Biosciences Inc. in the last 12-months were: Howard Levy (Buy at a value of $16 537), Nassim Usman (Buy at a value of $5 599), Nassim Usman (Option Excercise at a value of $23 150)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
1 (50.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.00
Strong Buy
1.00

Catalyst Biosciences Inc.

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes on product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

CEO: Nassim Usman

Telephone: +1 650 871-0761

Address: 611 Gateway Boulevard, South San Francisco 94080, CA, US

Number of employees: 34

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

56%44%

Bearish Bullish

58%42%

News

Stocktwits